Multipurpose prevention approaches with antiretroviral-based formulations
We compared the preclinical safety and efficacy of Tenofovir (TFV) 1% gel and MZC gel containing 50 μM MIV-150 (M), 14 mM Zn(O_2CCH_3)_2(H2O)2 (Z) and 3% carrageenan (C) through a series of in vitro, ex vivo and in vivo assays. Both gels showed good antiviral therapeutic indexes ( > 25-800). MZC showed greater anti-SHIV-RT activity than TFV 1% gel in rhesus macaque vaginal explants. MZC protected mice from vaginal HSV-2 challenge (p < 0.0001), but the TFV 1% gel did not.
Jean-Pierre, Ninochka, Patrick Barnable, Larisa Kizima, Aixa Rodriguez, Samantha Seidor, Michael Cooney, Meredith R. Clark, Gustavo F. Doncel, Melissa Robbiani, Thomas Zydowsky, Natalia Teleshova, and José Fernández-Romero. 2016. "Multipurpose prevention approaches with antiretroviral-based formulations," Antimicrobial Agents and Chemotherapy 60: 1141–1144.
Developing an ARV-Based Microbicide Gel